A5027218847- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Liver Disease and Transplantation
- Diabetes and associated disorders
- HIV/AIDS drug development and treatment
- Palliative Care and End-of-Life Issues
- Liver Diseases and Immunity
- Cytomegalovirus and herpesvirus research
- Systemic Lupus Erythematosus Research
- Immune Cell Function and Interaction
- Blood groups and transfusion
- Family Support in Illness
- Animal Virus Infections Studies
- Immunodeficiency and Autoimmune Disorders
- Viral gastroenteritis research and epidemiology
- RNA Interference and Gene Delivery
- Intergenerational Family Dynamics and Caregiving
- COVID-19 Clinical Research Studies
- Drug-Induced Hepatotoxicity and Protection
- Family and Patient Care in Intensive Care Units
- Chronic Lymphocytic Leukemia Research
- Clinical practice guidelines implementation
- MicroRNA in disease regulation
King's College Hospital
2015-2025
King's College Hospital NHS Foundation Trust
2009-2023
King's College London
2007-2023
Leeds General Infirmary
2023
University of Nottingham
2023
Macmillan Cancer Support
2018
Hospice UK
2018
Guy's and St Thomas' NHS Foundation Trust
2010-2018
University of Cambridge
2009-2014
King's College School
2010-2013
Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of scores during ETV treatment an ethnically diverse Western population.We studied all HBV monoinfected patients treated with from 11 European referral centres within the VIRGIL Network.A total 744 were included; 42% Caucasian, 29% Asian, 19% other, 10% unknown. At baseline, 164 (22%) had cirrhosis. During a median follow-up 167 (IQR 82-212)...
Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance a subset of patients. However, predictors loss after NUC remain ill-defined.We studied global cohort HBeAg-negative patients with undetectable HBV DNA who discontinued long-term therapy. Patients requiring retreatment treatment cessation were considered non-responders.We enrolled 1,216 (991 genotype data); 98 (8.1%) achieved loss. The probability was higher non-Asian (adjusted hazard ratio [aHR] 8.26, p <0.001), and lower...
Diagnostic criteria for autoimmune hepatitis (AIH) have been created and revised by the International Autoimmune Hepatitis Group (IAIHG). Simplified created, but remain independently unvalidated. We report on diagnostic accuracy of simplified in patients across a range diagnoses, including subset presenting with fulminant liver failure who required transplant. Patients AIH non-AIH etiologies disease were identified from dedicated patient databases. Parameters relevant to 1999 IAIHG recorded,...
A dichotomous separation of hepatitis B viral DNA and surface antigen (HBsAg) concentrations occurs during the natural history treatment chronic B. We have evaluated ability virus (HBV) RNA core-related (HBcrAg) as surrogates silencing covalently closed circular (cccDNA), to characterize this dissociation, virological outcomes.Three cohorts e (HBeAg)-negative patients were studied: cohort A: 66 HBeAg-negative on long-term nucleos(t)ide analogue (NA) therapy; B: 23 antibodies against...
Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels hepatitis B core-related antigen (HBcrAg) and surface (HBsAg) outcome after cessation.Patients who discontinued NA in centers Asia Europe were enrolled. HBcrAg HBsAg measured at treatment cessation, associations with off-treatment outcomes explored. The SCALE-B (Surface antigen, Core-related Age, ALT, tenofovir for HBV) score was calculated as...
<h2>Summary</h2> Nucleoside analogues are the mainstay of treatment for patients with chronic HBV infection but have no direct effect on covalently closed circular DNA. Long-term viral suppression is now routine, desirable endpoint functional cure rarely achieved. Newer therapies, targeting other aspects replicative life cycle HBV, present opportunities to deliver finite therapy and ‘cure'. This an area keen focus community. We describe a severe case hepatitis B reactivation, occurring...
NK cells are important antiviral effectors, highly enriched in the liver, with potential to regulate immunopathogenesis persistent viral infections. Here we examined whether changes pool induced when patients eAg-positive CHB 'primed' PegIFNα and importantly, these sustained or further modulated long-term after switching nucleos(t)ides (sequential NUC therapy), an approach currently tested clinic. Longitudinal sampling of a prospectively recruited cohort eAg+CHB showed that cumulative...
Hepatitis E (HEV) is a common infection worldwide and an emerging disease in developed countries. The presence of extra-hepatic manifestation HEV important to bear mind so that the diagnosis not missed, since routinely tested for acute hepatitis due perceived rarity this outside endemic This article reviews neurological presentations chronic HEV, discusses viral kinetics against symptomatology, outcomes specific treatment. Possible mechanisms pathogenesis are considered.
<h3>Objective</h3> To determine the prevalence and nature of palliative care needs in people aged 65 years or more (65+) who die emergency departments (EDs). <h3>Methods</h3> This was a retrospective analysis routine hospital data from two EDs South London. Patients 65+ living hospitals9 catchment area died ED during 1 year period (2006–2007) were included. Palliative identified by diagnosis symptoms, problems likely to benefit documented clinical records 3 months prior final attendance...
The aim of the study was to investigate longitudinally hepatitis B virus (HBV)-specific T-cell reactivity and viral behavior versus treatment response in tolerant children during combined antiviral therapy. Twenty-three with infancy-acquired (HBeAg(+)) belonging a published pilot 1-year lamivudine/alpha interferon (IFN-α) were investigated. Five seroconverted anti-HBs (responders). Nine HLA-A2(+) (4 responders 5 nonresponders). Mutations within HBV core gene determined at baseline liver...
Summary HBeAg seroconversion marks an important spontaneous change and treatment end‐point for HBeAg‐positive patients is a pre‐requisite HBsAg loss or functional cure. In this retrospective analysis, we aimed to identify predictors of using serum quantitative HBcrAg, in treated with nucleos(t)ide analogues (NA). Data samples from 118 adults (genotypes A‐G) started on NA between Jan 2005 Sept 2016 were retrospectively analysed at several time‐points. The predictive power on‐treatment levels...
Summary Background An accurate, single‐point differential diagnosis between HBeAg‐negative infection (ENI) and chronic hepatitis B (CHB) is an unmet need. Aims To assess the diagnostic value of new core‐related antigen (HBcrAg) assay. Methods A retrospective anonymised data analysis was performed in a multicentre European (nine centres six countries) cohort 1582 consecutive HBsAg‐positive/HBeAg‐negative subjects classified according to EASL guidelines as: 550‐CHB, 710‐ENI 322‐GZ (grey‐zone,...
Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up.
Summary. Historically, liver biopsy (LB) was the sole method to evaluate severity of hepatic fibrosis in patients with chronic hepatitis C infection. However, LB is expensive and associated a risk severe complications. Therefore, noninvasive tests have been developed assess fibrosis. The accuracy Fibroscan (FS) King’s score (KS) evaluated individually combination using histology as reference standard. One hundred eighty‐seven were identified who had undergone diagnosis virus (HCV)...